Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA 92093, USA.
School of Medicine, University of California, San Diego, CA 92093, USA.
Int J Mol Sci. 2021 Mar 10;22(6):2784. doi: 10.3390/ijms22062784.
Vancomycin is commonly used as a first line therapy for gram positive organisms such as methicillin resistant . Vancomycin-induced acute kidney injury (V-AKI) has been reported in up to 43% of patients, especially in those with higher targeted trough concentrations. The precise mechanism of injury in humans remains elusive, with recent evidence directed towards proximal tubule cell apoptosis. In this study, we investigated the protein contents of urinary exosomes in patients with V-AKI to further elucidate biomarkers of mechanisms of injury and potential responses.
Urine samples from patients with V-AKI who were enrolled in the DIRECT study and matched healthy controls from the UAB-UCSD O'Brien Center Biorepository were included in the analysis. Exosomes were extracted using solvent exclusion principle and polyethylene glycol induced precipitation. Protein identity and quantification was determined by label-free liquid chromatography mass spectrometry (LC/MS). The mean peak serum creatinine was 3.7 ± 1.4 mg/dL and time to kidney injury was 4.0 ± 3.0 days. At discharge, 90% of patients demonstrated partial recovery; 33% experienced full recovery by day 28. Proteomic analyses on five V-AKI and 7 control samples revealed 2009 proteins in all samples and 251 proteins significantly associated with V-AKI (Pi-score > 1). The top discriminatory proteins were complement C3, complement C4, galectin-3-binding protein, fibrinogen, alpha-2 macroglobulin, immunoglobulin heavy constant mu and serotransferrin.
Urinary exosomes reveal up-regulation of inflammatory proteins after nephrotoxic injury in V-AKI. Further studies are necessary in a large patient sample to confirm these findings for elucidation of pathophysiologic mechanisms and validation of potential injury biomarkers.
万古霉素常用于治疗耐甲氧西林的革兰氏阳性菌等。万古霉素诱导的急性肾损伤(V-AKI)在高达 43%的患者中都有报道,尤其是那些目标谷浓度较高的患者。在人类中,损伤的确切机制仍难以捉摸,最近的证据指向近端肾小管细胞凋亡。在这项研究中,我们研究了 V-AKI 患者尿液外泌体中的蛋白质含量,以进一步阐明损伤机制和潜在反应的生物标志物。
本研究纳入了 DIRECT 研究中的 V-AKI 患者和 UAB-UCSD O'Brien 中心生物标本库中匹配的健康对照者的尿液样本。使用溶剂排除原理和聚乙二醇诱导沉淀法提取外泌体。通过无标记液相色谱-质谱(LC/MS)法确定蛋白质的种类和含量。平均血清肌酐峰值为 3.7±1.4mg/dL,发生肾损伤的时间为 4.0±3.0 天。出院时,90%的患者部分恢复,33%的患者在第 28 天完全恢复。对 5 例 V-AKI 和 7 例对照样本的蛋白质组学分析显示,所有样本中有 2009 种蛋白质,有 251 种蛋白质与 V-AKI 显著相关(Pi 评分>1)。最具区分性的蛋白质是补体 C3、补体 C4、半乳糖凝集素-3 结合蛋白、纤维蛋白原、α-2 巨球蛋白、免疫球蛋白重链μ和转铁蛋白。
尿外泌体显示 V-AKI 肾毒性损伤后炎症蛋白的上调。需要在更大的患者样本中进一步研究以证实这些发现,以阐明病理生理机制和验证潜在的损伤生物标志物。